drugset / Trial / NCT00122434
Dose Finding Study in COPD
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to determine the optimum dose of BEA 2180 BR inhalation solut ion delivered by the Respimat ? inhaler once daily for four weeks in patients with COPD.
Timeline
- Start
- 2005-07
- Primary completion
- 2006-05
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BEA 2180 BR | Unknown | — | Inhaled |
| Subject | Tiotropium | Other / unclassified | — | — |